npj Breast Cancer

New collections open to submissions

Featured

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Jun Ma
Jack Junjie Chan
Yoon-Sim Yap
Review ArticleOpen Access08 Sept 2023
Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

Mohammadhadi Khorrami
Vidya Sakar Viswanathan
Anant Madabhushi
ArticleOpen Access11 Aug 2023

Announcements

npj Breast Cancer Journal Metrics

npj Breast Cancer has a 2-year impact factor of 5.9 (2022), article downloads of 742,276 (2022) and 7 days from submission to first editorial decision (2022).
Call for papers: AI in precision oncology

Submit to our new collection focused on AI in precision oncology, deadline: 19 October 2023.
Call for papers: blood biomarkers in breast cancer

Submit to our new collection focused on blood biomarkers in breast cancer, deadline: 31 January 2024.
Follow us on Twitter

Keep up to date with the journal and new publications by following us on Twitter. Share your work by tagging @Nature_NPJ and using our hashtag #npjBCancer.

Browse articles

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

Akshara Singareeka Raghavendra
Nicole M. Kettner
Debu Tripathy
ArticleOpen Access26 Jan 2025
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes

Fresia Pareja
Rohit Bhargava
Steffi Oesterreich
Review ArticleOpen Access24 Jan 2025
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality

Noor A. M. Bakker
Hannah Garner
Karin E. de Visser
ArticleOpen Access23 Jan 2025
Racial discrimination among women seeking breast cancer care

Lauren J. Oshry
Ruth I. Lederman
Naomi Y. Ko
ArticleOpen Access16 Jan 2025
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden

Qianying Zuo
Jin Young Yoo
Zeynep Madak-Erdogan
ArticleOpen Access14 Jan 2025
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

Laura M. Spring
Lauren Scarpetti
Aditya Bardia
ArticleOpen Access07 Jan 2025
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling

Xi Xiao Huang
Ley Moy Ng
Bin Tean Teh
ArticleOpen Access03 Jan 2025
The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer

Zheqi Li
Fangyuan Chen
Adrian V. Lee
ArticleOpen Access19 Dec 2024
Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

Kung-Chi Chang
Francesca Silvestri
Joan S. Brugge
ArticleOpen Access19 Dec 2024

Trending - Altmetric

Science jobs

Head of the gynecology Service with an Associate or Full Professor title

UNIL (University of Lausanne) is a leading international teaching and research institution, with over 5,000 employees and 15,500 students spread ac...

Lausanne, Canton of Vaud (CH)

University of Lausanne (UNIL)
Postdoctoral fellowship in cancer biomarkers research

Postdoctoral fellowship in cancer biomarkers, center for primary health care research, Department of Clinical Sciences Malmö, Sweden.

Malmö (Stad), Skåne (SE)

Lund University
Tenure-Track Junior PI in Artificial Intelligence for precision oncology

Milan City (IT)

IFOM ETS - The AIRC Institute of Molecular Oncology
Assistant Professor of Applied Viticulture

University of California, Davis is recruiting an Assistant Professor with an emphasis in applied viticulture.

Davis, California

University of California Davis
Postdoc in Radiopharmaceutical Development for Cancer Treatment

Make a lasting impact in the fight against cancer

Odense, Fyn (DK)

University of Southern Denmark (SDU)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.

New collections open to submissions

Featured

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

Announcements

npj Breast Cancer Journal Metrics

Call for papers: AI in precision oncology

Call for papers: blood biomarkers in breast cancer

Follow us on Twitter

Browse articles

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes

Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality

Racial discrimination among women seeking breast cancer care

Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling

The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer

Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

Trending - Altmetric

Science jobs

Head of the gynecology Service with an Associate or Full Professor title

Postdoctoral fellowship in cancer biomarkers research

Tenure-Track Junior PI in Artificial Intelligence for precision oncology

Assistant Professor of Applied Viticulture

Postdoc in Radiopharmaceutical Development for Cancer Treatment

Search

Quick links

Featured

Announcements

Advertisement

Trending - Altmetric

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer

Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden

Sustained lymphocyte decreases after treatment for early breast cancer

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes

Search

Quick links